Periodontal Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Nov. 16, 2011 - PRLog -- GlobalData estimated the global periodontal disease therapeutics market to be valued at $1,607m in 2010. It is expected to grow at a compound annual growth rate (CAGR) of approximately 6.4% and reach $2,638m in 2018. The treatment of periodontal disease is dominated by dental procedures and techniques such as scaling and root planing (SRP) and surgery. Additionally, the locally applied antibiotics (LAAs) and systemic applied antibiotics are used as adjunctive/maintenance therapies. The LAAs and systemic antibiotics commonly prescribed for periodontal disease include Periochip (chlorhexidine), Arestin (minocycline), Atridox (doxycycline) and Periostat (low dose doxycycline). During the historical period 2005-2010, a major barrier for the periodontal disease therapeutics market was the limited awareness among individuals about the disease. Fear of pain during surgery and costs related with the treatment procedures resulted in low treatment rates. However, due to the efforts of National Institute of Dental and Craniofacial Research (NIDCR) and National Institute of Health (NIH), these inhibitions have reduced over the past couple of years, importantly; this trend is likely to continue in the future, thereby resulting in an increase in the treatment rates. The increasing prevalence of periodontal disease is a major factor for growth of the market, moreover, it is estimated that the prevalence of periodontal disease would continue to increase through the forecast period 2018.

GlobalData’s analysis suggests that the current market comprises of drugs such as Periochip, Arestin, Atridox, Periostat and generics such as doxycyline and minocycline. All of these drugs are used as an adjuvant therapy to scaling, root planing and flap surgery. Periochip, Arestin, Atridox are LAAs that are applied to the gum pockets after SRP. These LAAs help in quick healing of the gum pockets. The medical practitioners continue to prefer surgery, SRP techniques over LAAs, due to the low efficacy of these LAAs and lack of alternative therapies substituting surgery. The current periodontal disease therapeutics market needs novel drugs with better efficacy profiles than the existing molecules. Drugs with novel mechanism to regenerate periodontal tissues affected by periodontitis and the ability to significantly reduce pocket depths are likely to have a significant impact on the periodontal disease treatment paradigm. Such therapies being introduced into the market is likely to increase treatment rates but reduce the unmet needs of the current market.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....

GlobalData, the industry analysis specialist’s new report, “Periodontal Disease Therapeutics – Pipeline Assessment and Market Forecasts to 2018” is an essential source of information and analysis on the global periodontal disease market. The report identifies the key trends shaping and driving the global
periodontal disease market. The report also provides insight on the prevalent competitive landscape and
the emerging players expected to bring a significant shift in the market positioning of the existing market leaders. Most importantly, the report provides a valuable insight on the pipeline products within the global periodontal disease sector. GlobalData estimated the global periodontal disease therapeutics market to be valued at $1,607m in 2010. It is expected to grow at a compound annual growth rate (CAGR) of approximately 6.4% and reach $2,638m in 2018. The treatment of periodontal disease is dominated by dental procedures and techniques such as scaling, root planing and surgery. Additionally, the locally applied antibiotics (LAAs) and systemic applied antibiotics are used as adjunctive/maintenance therapies. The LAAs and systemic antibiotics commonly prescribed for periodontal disease include Periochip (chlorhexidine), Arestin (minocycline), Atridox (doxycycline) and Periostat (low dose doxycycline). During the historical period 2005-2010, a major barrier for the periodontal disease therapeutics market was limited awareness among the individuals about the disease. Fear of pain during surgery and costs related with the treatment procedures resulted in low treatment rates. However, due to the efforts of National Insitute of Dental and Craniofacial Research (NIDCR) and National Institute of Health (NIH), these inhibitions have reduced over the past couple of years, importantly; this trend is likely to continue in the future, thereby resulting in an increase in treatment rates. Increasing prevalence of periodontal disease is a major factor for growth of the market, moreover, it is estimated that the prevalence of periodontal disease would continue to increase through the forecast period 2018.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Peri...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.